SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia
Genes · 15.01.2024 · 15 (1) · 99
DOI: 10.3390/genes15010099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 15.01.2024. Verfasst von Jonathan B Wagner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ward Family Heart Center, Children's Mercy, Kansas City, MO 64108, USA. Hauptthemen laut MEDLINE: Hypercholesterolemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, Marion Merrell Dow Clinical Scholar Award.
Abstract (Originalsprache)
This clinical study examined the influence of SLCO1B1 c.521T>C (rs4149056) on plasma atorvastatin concentrations in pediatric hypercholesterolemia. The participants (8–21 years), including heterozygous (c.521T/C, n = 13), homozygous (c.521C/C, n = 2) and controls (c.521T/T, n = 13), completed a single-oral-dose pharmacokinetic study. Similar to in adults, the atorvastatin (AVA) area-under-concentration-time curve from 0 to 24 h (AUC0–24) was 1.7-fold and 2.8-fold higher in participants with c.521T/C and c.521C/C compared to the c.521T/T participants, respectively. The inter-individual variability in AVA exposure within these genotype groups ranged from 2.3 to 4.8-fold, indicating that additional factors contribute to the inter-individual variability in the AVA dose–exposure relationship. A multivariate model reinforced the SLCO1B1 c.521T>C variant as the central factor contributing to AVA systemic exposure in this pediatric cohort, accounting for ~65% of the variability in AVA AUC0–24. Furthermore, lower AVA lactone concentrations in participants with increased body mass index contributed to higher exposure within the c.521T/T and c.521T/C genotype groups. Collectively, these factors contributing to higher systemic exposure could increase the risk of toxicity and should be accounted for when individualizing the dosing of atorvastatin in eligible pediatric patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ward Family Heart Center, Children's Mercy, Kansas City, MO 64108, USA.
- Division of Clinical Pharmacology and Toxicology, Children's Mercy, Kansas City, MO 64108, USA.
- Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA.
- Health Services & Outcomes Research, Children's Mercy, Kansas City, MO 64108, USA.
- Clinical Pharmacology Shared Resource, University of Kansas Cancer Center, Fairway, KS 66205, USA.
ORCID-Profile: Jonathan B Wagner, Andrea Gaedigk, Roger Gaedigk, J Steven Leeder
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- Marion Merrell Dow Clinical Scholar Award
- Children’s Mercy Hospital Fellow Clinical Scholar Award and the Ward Family Heart Center
- NCATS
- University of Kansas Cancer Center
Zitieren
APA
Wagner, J. B., Abdel-Rahman, S., Raghuveer, G., Gaedigk, A., Boone, E. C., Gaedigk, R., Staggs, V. S., Reed, G. A., Zhang, N., & Leeder, J. S. (2024). SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes, 15(1), 99. https://doi.org/10.3390/genes15010099
Vancouver
Wagner JB, Abdel-Rahman S, Raghuveer G, Gaedigk A, Boone EC, Gaedigk R, et al. SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes. 2024;15(1):99. doi:10.3390/genes15010099
BibTeX
@article{Wagner2024,
author = {Wagner, Jonathan B and Abdel-Rahman, Susan and Raghuveer, Geetha and Gaedigk, Andrea and Boone, Erin C and Gaedigk, Roger and Staggs, Vincent S and Reed, Gregory A and Zhang, Na and Leeder, J Steven},
title = {SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia},
journal = {Genes},
year = {2024},
volume = {15},
number = {1},
pages = {99},
doi = {10.3390/genes15010099}
}
EUVIMED